Madrigal Pharmaceuticals, Inc.
Clinical trials sponsored by Madrigal Pharmaceuticals, Inc., explained in plain language.
-
Hope for NASH: new pill aims to reverse liver damage and prevent cirrhosis
Disease control OngoingThis Phase 3 trial tests whether the drug resmetirom (MGL-3196) can reverse liver scarring (fibrosis) and stop NASH from progressing to cirrhosis or liver failure. About 1,759 adults with NASH and liver fibrosis will receive either resmetirom or a placebo daily for up to 54 month…
Phase: PHASE3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 24, 2026 03:06 UTC
-
Hope for NASH cirrhosis: new pill aims to prevent liver failure
Disease control OngoingThis study tests a daily pill called resmetirom in people with NASH-related cirrhosis (scarring of the liver). The goal is to see if it can delay or prevent serious liver problems like liver failure, need for a transplant, or death. About 845 adults with well-compensated cirrhosi…
Phase: PHASE3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:47 UTC
-
New pill shows promise for fatty liver in major trial
Disease control OngoingThis study tests a daily pill called resmetirom in people with non-alcoholic fatty liver disease (NAFLD). The goal is to see if it safely reduces liver fat and cholesterol over 52 weeks. About 810 adults who completed earlier related studies are taking part. This is a long-term t…
Phase: PHASE3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC